Affluent Medical announces coverage initiation

of its stock by Gilbert Dupont – Société Générale Group

Aix-en-Provence, 4 April 2024 - 5:45 pm - Affluent Medical (ISIN: FR0013333077 – Ticker: AFME), a French clinical-phase MedTech company specializing in the international development and industrialization of innovative medical prostheses, announces today that Gilbert Dupont – Société Générale Group has initiated coverage of its stock.

Gilbert Dupont – Société Générale Group began covering the stock with a study entitled "Un pour tous, tous pour un" ("one for all and all for one"), published on 3 April 2024. In this study, Gilbert Dupont – Société Générale Group recommended buying the stock, with a target price of €3.30, representing a potential upside of 89% compared with the closing price on 2 April 2024.

This initiation completes the coverage of Affluent Medical's stock and adds to the financial analyst consensus alongside Invest Securities, Kepler Cheuvreux, Portzamparc BNP Paribas Group, and TP ICAP Midcap.

About Affluent Medical

Affluent Medical is a French MedTech company, founded by Truffle Capital, with the ambition to become a global leader in the treatment of structural heart diseases, which are the world's leading cause of mortality, and urinary incontinence, which currently affects one in four adults.

Affluent Medical develops next-generation, mini-invasive, innovative, adjustable, and biomimetic implants to restore critical physiological functions. The product candidates developed by the Company are currently all in clinical studies.

Subject to raising the necessary funds to finance its strategy and to positive results from ongoing clinical studies, the Company's ambition is to gradually commercialize its products early 2026. For more information, visit www.affluentmedical.com

Contacts: